Total = 3984 | Any Peripheral Manifestation | p1 | ||
---|---|---|---|---|
Yes = 2562, n (%) | No = 1422, n (%) | |||
NSAID | ||||
N (%) patients since the onset of SpA symptoms | 3548 (89.0) | 2326 (90.8) | 1222 (85.9) | < 0.001 |
DMARD intake, past or present, n (%) | ||||
csDMARD | 2371 (59.5) | 1825 (71.2) | 546 (38.4) | < 0.001 |
bDMARD | 1742 (43.7) | 1236 (48.2) | 506 (35.6) | < 0.001 |
Corticosteroids | ||||
% of patients using corticosteroids | 1523 (38.2) | 1223 (47.7) | 300 (21.1) | < 0.001 |
Current prednisone intake, mg, mean (SD) | 1.01 (4.18) | 1.35 (4.82) | 0.39 (2.53) | < 0.001 |
Estimated total intake, mg, mean (SD) | 1741 (6901) | 2388 (8047) | 576 (3827) | < 0.001 |
↵1 Chi-square and t test for qualitative and quantitative variables, respectively. Percentages indicate no. patients with the covariate from the total no. patients in each column. NSAID: nonsteroidal antiinflammatory drugs; SpA: spondyloarthritis; DMARD: disease-modifying antirheumatic drugs; csDMARD: conventional synthetic DMARD; bDMARD: biological DMARD.